Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)

Conditions: Metastatic Esophageal Cancer; Metastatic Gastric Cancer Interventions: Drug: Single agent zimberelimab; Drug: Combination zimberelimab + domvanalimab Sponsors: Royal Marsden NHS Foundation Trust; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials